<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33614">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108119</url>
  </required_header>
  <id_info>
    <org_study_id>PRO008</org_study_id>
    <nct_id>NCT02108119</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <authority>The Netherlands: Ethical committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment</study_design>
  <primary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>28 days</time_frame>
    <description>0-10 numeric rating scale (NRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control placebo</intervention_name>
    <arm_group_label>Control placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Age ≥18 and ≤70 years at Visit 1

          -  IBS according to the Rome III criteria

          -  A score on abdominal pain NRS ≥3 and ≤6 at least two days a week measured the weeks
             before Visit 2 (baseline)

          -  IBS-SSS  ≥75 and ≤300 at Visit 2 (baseline)

          -  Ability and willingness to understand and comply with the study procedures

        Exclusion Criteria:

          -  Known intolerance or allergy to milk products (protein or lactose) or gluten

          -  History of alcohol or substance abuse six months prior to screening

          -  Known Hepatitis B or C or Human Immunodeficiency Virus (HIV) 1 or 2

          -  Female patients: currently pregnant or breast-feeding or intending to become pregnant
             during the study

          -  Abnormal results of the screening laboratory tests  clinically relevant for study
             participation, as judged by the Investigator

          -  Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by
             the Investigator

          -  Other severe disease(s) such as malignancy, severe coronary disease, kidney disease
             or neurological disease, as judged by the Investigator

          -  Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss
             of weight or fever, as judged by the Investigator

          -  Severe psychiatric disease as judged by the Investigator

          -  Lack of suitability for participation in the study for any reason as judged by the
             Investigator

          -  Use of other probiotic products from Visit 1 and throughout the study.

          -  Consumption of antibiotic drugs 1 month prior to screening and throughout the study.

          -  Consumption of drugs on a regular basis which could interfere with symptom evaluation
             as judged by the Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Vivienne van de Walle, Med dr</last_name>
    <phone>+31 46 475 8687</phone>
    <email>vivienne.vandewalle@ptr.nu</email>
  </overall_contact>
  <location>
    <facility>
      <name>PreCare Trial &amp; Recruitment</name>
      <address>
        <city>Beek</city>
        <zip>6191</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vivienne van de Walle, Med dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
